U.S. Alzheimers Therapeutics Market Size & Outlook
U.S. alzheimers therapeutics market, 2018-2030 (US$M)
Related Markets
U.S. alzheimers therapeutics market highlights
- The U.S. alzheimers therapeutics market generated a revenue of USD 1,590.0 million in 2022 and is expected to reach USD 6,441.3 million by 2030.
- The U.S. market is expected to grow at a CAGR of 19.1% from 2023 to 2030.
- In terms of segment, cholinesterase inhibitors was the largest revenue generating drug class in 2022.
- Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.
Alzheimers therapeutics market data book summary
| Market revenue in 2022 | USD 1,590.0 million |
| Market revenue in 2030 | USD 6,441.3 million |
| Growth rate | 19.1% (CAGR from 2022 to 2030) |
| Largest segment | Cholinesterase inhibitors |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs, Monoclonal Antibodies |
| Key market players worldwide | Eisai Co Ltd, Novartis AG ADR, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Roche Holding AG ADR, Daiichi Sankyo Co Ltd, Johnson & Johnson, AC Immune SA |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.8% of the global alzheimers therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. alzheimers therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 6,441.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Alzheimers Therapeutics Market Scope
Alzheimers Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. alzheimers therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.
Cholinesterase inhibitors was the largest segment with a revenue share of 51.49% in 2022. Horizon Databook has segmented the U.S. alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs, monoclonal antibodies covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest market for Alzheimer's drugs and leads with a lucrative share of the global market. Symptomatic and disease- modifying drugs remain the primary drug class over the forecast period.
The high prevalence of AD in this country is estimated to drive growth of this market. The number of people with AD and other dementia is increasing along with rising older population. It is considered the 6th leading cause of death in America.
Market players are extensively engaged in R&D for new drug development. Currently, six drugs are approved by the U.S. FDA to treat symptoms of AD, temporarily helping memory and thinking problems. In July 2021, the U.S. FDA approved Biogen's aducanumab for AD treatment. This was the sixth drug for the disease.
Reasons to subscribe to U.S. alzheimers therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. alzheimers therapeutics market databook
-
Our clientele includes a mix of alzheimers therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. alzheimers therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. alzheimers therapeutics market size, by drug class, 2018-2030 (US$M)
U.S. Alzheimers Therapeutics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
